Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-Cell responses to the tumor-specific antigen NY-ESO-1

被引:55
|
作者
Le Gal, FA
Ayyoub, M
Dutoit, V
Widmer, V
Jäger, E
Cerottini, JC
Dietrich, PY
Valmori, D
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Med, Ludwig Inst,Clin Trial Ctr,Div Med Oncol, New York, NY 10032 USA
[2] Univ Hosp Geneva, Div Oncol, Lab Tumor Immunol, Geneva, Switzerland
[3] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[4] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
关键词
T-cell receptor; repertoire; tumor immunity; vaccination;
D O I
10.1097/01.cji.0000161398.34701.26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epilope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines. but they are heterogeneous in terms of functional avidity and tumor reactivity, The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may rail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.
引用
收藏
页码:252 / 257
页数:6
相关论文
共 50 条
  • [1] Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1
    Jackson, Heather
    Dimopoulos, Nektaria
    Mifsud, Nicole A.
    Tai, Tsin Yee
    Chen, Qiyuan
    Svobodova, Suzanne
    Browning, Judy
    Luescher, Immanuel
    Stockert, Lisa
    Old, Lloyd J.
    Davis, Ian D.
    Cebon, Jonathan
    Chen, Weisan
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 176 (10): : 5908 - 5917
  • [2] Striking immunodominance hierarchy of naturally-occurring CD8+ and CD4+ T cell responses to turnour antigen NY-ESO-1
    Jackson, HM
    Dimopoulos, N
    Mifsud, NA
    Tai, T
    Chen, Q
    Svobodova, S
    Browning, J
    Luescher, I
    Stockert, L
    Old, LJ
    Davis, ID
    Cebon, J
    Chen, W
    [J]. TISSUE ANTIGENS, 2005, 66 (05): : 451 - 451
  • [3] Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers
    Ayyoub, Maha
    Pignon, Pascale
    Dojcinovic, Danijel
    Raimbaud, Isabelle
    Old, Lloyd J.
    Luescher, Immanuel
    Valmori, Danila
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (18) : 4607 - 4615
  • [4] Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer
    Karanikas, Vaios
    Zamanakou, Maria
    Soukou, Faye
    Kerenidi, Theodora
    Gourgoulianis, Konstantinos I.
    Germenis, Anastasios E.
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2010, 88 (05): : 575 - 585
  • [5] Multiepitope CD8+ T cell response to an NY-ESO-1 peptide vaccine results in imprecise tumor targeting
    Dutoit, V
    Taub, RN
    Papadopoulos, KP
    Talbot, S
    Keohan, ML
    Brehm, M
    Gnjatic, S
    Harris, PE
    Bisikirska, B
    Guillaume, P
    Cerottini, JC
    Hesdorffer, CS
    Old, LJ
    Valmori, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (12): : 1813 - 1822
  • [6] Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination
    Karbach, Julia
    Gnjatic, Sacha
    Pauligk, Claudia
    Bender, Armin
    Maeurer, Markus
    Schultze, Joachim L.
    Nadler, Kerstin
    Wahle, Claudia
    Knuth, Alexander
    Old, Lloyd J.
    Jaeger, Elke
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (09) : 2042 - 2048
  • [7] Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication
    Chaoul, Nada
    Fayolle, Catherine
    Desrues, Belinda
    Oberkampf, Marine
    Tang, Alexandre
    Ladant, Daniel
    Leclerc, Claude
    [J]. CANCER RESEARCH, 2015, 75 (16) : 3279 - 3291
  • [9] Antigen-specific immunity in neuroblastoma patients: Antibody and T-cell recognition of NY-ESO-1 tumor antigen
    Rodolfo, M
    Luksch, R
    Stockert, E
    Chen, YT
    Collini, P
    Ranzani, T
    Lombardo, C
    Dalerba, P
    Rivoltini, L
    Arienti, F
    Fossati-Bellani, F
    Old, LJ
    Parmiani, G
    Castelli, C
    [J]. CANCER RESEARCH, 2003, 63 (20) : 6948 - 6955
  • [10] Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients:: Correlation with antibody responses
    Gnjatic, S
    Atanackovic, D
    Jäger, E
    Matsuo, M
    Selvakumar, A
    Altorki, NK
    Maki, RG
    Dupont, B
    Ritter, G
    Chen, YT
    Knuth, A
    Old, LJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) : 8862 - 8867